Perennial Investment Advisors LLC Grows Position in Axon Enterprise, Inc $AXON

Perennial Investment Advisors LLC lifted its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 12.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 918 shares of the biotechnology company’s stock after buying an additional 101 shares during the period. Perennial Investment Advisors LLC’s holdings in Axon Enterprise were worth $760,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. TCTC Holdings LLC lifted its stake in Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 24 shares in the last quarter. Banque Transatlantique SA acquired a new position in Axon Enterprise during the first quarter worth $31,000. Flaharty Asset Management LLC purchased a new stake in Axon Enterprise in the 1st quarter valued at $33,000. Hemington Wealth Management grew its holdings in Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares in the last quarter. Finally, Whipplewood Advisors LLC increased its stake in shares of Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analyst Ratings Changes

AXON has been the subject of several recent analyst reports. Zacks Research cut shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Piper Sandler lowered their price target on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. UBS Group reduced their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Barclays decreased their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Finally, Royal Bank Of Canada assumed coverage on shares of Axon Enterprise in a research report on Monday. They set an “outperform” rating and a $860.00 price target for the company. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $814.00.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $533.77 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91. The firm has a market cap of $42.12 billion, a PE ratio of 131.80, a price-to-earnings-growth ratio of 29.49 and a beta of 1.45. The company’s 50 day moving average is $694.97 and its two-hundred day moving average is $734.66.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm’s revenue was up 30.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.45 EPS. On average, research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $743.64, for a total transaction of $7,436,400.00. Following the sale, the chief executive officer owned 3,043,982 shares in the company, valued at $2,263,626,774.48. This represents a 0.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Brittany Bagley sold 5,000 shares of the stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the sale, the chief financial officer directly owned 93,592 shares in the company, valued at $66,813,456.96. This represents a 5.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 38,622 shares of company stock valued at $26,439,364. Company insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.